Website profile

Tradingview

Where the world charts, chats and trades markets. We're a supercharged super-charting platform and social network for traders and investors. Free to sign up.

  • 22,608articles · 30d
  • 1+ day agolatest article
  • Aug 13, 2026earliest in window
  • 94%with images · 8 videos
  • 143avg words
articles per day
Categories
  • Economy, Business & Finance 21,429
  • Finance & Business 20,735
  • News 12,724
  • Finance 5,665
  • Business & Industrial 2,355
  • Industrial 617
  • Health & Wellness 359
  • Politics 270

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

TradingView
tradingview.com > news > urn:summary_document_transcript:quartr.com:4151752:0-mgx-lead-gene-editing-program-for-hemophilia-a-advances-to-clinic-with-strong-preclinical-results-and-funding

MGX: Lead gene editing program for Hemophilia A advances to clinic with strong preclinical results and funding

2+ day, 8+ hour ago   (81+ words) tradingview.com MGX: Lead gene editing program for Hemophilia A advances to clinic with strong preclinical results and funding The session highlighted a proprietary gene editing platform with a lead program, MGX-001, advancing toward clinical trials for Hemophilia A, showing…...

TradingView
tradingview.com > news > urn:summary_document_transcript:quartr.com:4137297:0-beam-durable-precise-base-editing-shows-strong-efficacy-and-safety-as-pivotal-trials-and-commercialization-advance

BEAM: Durable, precise base editing shows strong efficacy and safety as pivotal trials and commercialization advance

4+ day, 8+ hour ago   (79+ words) TradingView BEAM: Durable, precise base editing shows strong efficacy and safety as pivotal trials and commercialization advance Base editing platform enables precise, durable genetic corrections for multiple diseases, with new data showing robust efficacy and safety in alpha-1 antitrypsin deficiency....